Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.

Autor: Pérez-Valderrama B; Department of Medical Oncology, Virgen del Rocío University Hospitals, Sevilla bperezv@gmail.com., Arranz Arija JA; Department of Medical Oncology, Gregorio Marañón General University Hospital, Madrid., Rodríguez Sánchez A; Department of Medical Oncology, University Hospital of León, Leon., Pinto Marín A; Department of Medical Oncology, La Paz University Hospital, Madrid., Borrega García P; Department of Medical Oncology, San Pedro de Alcántara Hospital, Cáceres., Castellano Gaunas DE; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid., Rubio Romero G; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid., Maximiano Alonso C; Department of Medical Oncology, Puerta de Hierro University Hospital, Majadahonda (Madrid)., Villa Guzmán JC; Department of Medical Oncology, General University Hospital of Ciudad Real, Ciudad Real., Puertas Álvarez JL; Department of Medical Oncology, Rio Hortega University Hospital, Valladolid., Chirivella González I; Department of Medical Oncology, University Hospital of Valencia, Valencia., Méndez Vidal MJ; Department of Medical Oncology, Reina Sofía University Hospital, Córdoba., Juan Fita MJ; Department of Medical Oncology, Valencian Institute of Oncology, Valencia., León-Mateos L; Department of Medical Oncology, Santiago University Hospital Complex, Santiago de Compostela., Lázaro Quintela M; Department of Medical Oncology, University Hospital Complex of Vigo, Vigo., García Domínguez R; Department of Medical Oncology, Clinic University Hospital of Salamanca, Salamanca., Jurado García JM; Department of Medical Oncology, San Cecilio University Hospital, Granada., Vélez de Mendizábal E; Department of Medical Oncology, San Pedro Hospital, Logroño., Lambea Sorrosal JJ; Department of Medical Oncology, Lozano Blesa University Hospital, Zaragoza., García Carbonero I; Department of Medical Oncology, Virgen de la Salud Hospital, Toledo., González del Alba A; Department of Medical Oncology, Son Espases University Hospital, Palma de Mallorca., Suárez Rodríguez C; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona., Jiménez Gallego P; Department of Medical Oncology, Doctor Negrín University Hospital of Gran Canaria, Las Palmas de Gran Canaria., Meana García JA; Department of Medical Oncology, University Hospital of Alicante, Alicante., García Marrero RD; Department of Medical Oncology, University Hospital of Canarias, San Cristóbal de La Laguna (Santa Cruz de Tenerife)., Gajate Borau P; Department of Medical Oncology, Quirón University Hospital, Madrid., Santander Lobera C; Department of Medical Oncology, Miguel Servet University Hospital, Zaragoza., Molins Palau C; Department of Medical Oncology, Doctor Peset University Hospital, Valencia., López Brea M; Department of Medical Oncology, Marqués de Valdecilla University Hospital, Santander., Fernández Parra EM; Department of Medical Oncology, Nuestra Señora de Valme University Hospital, Sevilla., Reig Torras O; Department of Medical Oncology, Clinic University Hospital of Barcelona, Barcelona., Basterretxea Badiola L; Department of Medical Oncology, Donostia University Hospital, San Sebastián., Vázquez Estévez S; Department of Medical Oncology, Lucus Augusti University Hospital, Lugo., González Larriba JL; Department of Medical Oncology, San Carlos University Hospital, Madrid, Spain.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2016 Apr; Vol. 27 (4), pp. 706-11. Date of Electronic Publication: 2015 Dec 09.